Owlposting

Thank you to Jimmy Sastra and Kitchener D. Wilson for discussions relating to this piece. All opinions are my own. This essay is the first of three covering organoids. The full set is:Why haven't organoids solved all of drug discovery?UnreleasedUnreleased

IntroductionTimestampsTranscriptApple PodcastsSpotifyIntroductionBack in early May, I flew to North Carolina to interview Alex Rubinsteyn (left) and Benjamin Vincent (right). Together, they run the Personalized Immunotherapy Research Lab (PIRL) at UNC-Cha

Note: I've been traveling through Europe for the past week or so, and have not had time to finish my larger ongoing essays. So, this is a piece I wrote back in December 2025 about bioweapons programs. Also, a few friends and I are hosting an NYC meetup on

Grateful to Benjamin Vincent and Alex Rubinsteyn for our many conversations on this topic, and comments on drafts of this essay! Introduction The immunological theory behind cancer vaccinesThe past and present of TAA/CTA cancer vaccines The upcoming era o

There exist drug classes that seem, in retrospect, cursed. As these chemicals worm their way through the clinical trial system, they consume billions of dollars along the way, and squelch through thousands of sick patients. When finally it dawns on everyo

Note: this essay is connected to a prior one titled "Curious cases of financial engineering in biotech". I conclude that piece with the following paragraph: To end this off: I have deliberately left out China, which may be the most aggressive current exam

Note: finance topics are slightly sensitive, so, while nothing in this article contains proprietary information, I will not include the names of people I talked with for this piece. I appreciate everyone who reached out to help me put this together! Edit:

Introduction TimestampsTranscript Watch on Youtube, Apple Podcasts, or Spotify.Introduction After having written long-form essays over a weirdly diverse number of areas of the life-sciences, I am increasingly confident in my status as someone who knows a

Note: I'll be releasing a 2 hour long Podcast in a few weeks, interviewing an early-stage founder working at the extremely niche intersection of (biomanufacturing x printed circuit boards). Please reach out to me at [email protected] or on X if you'd b

Owl Posting turned two this month. It's difficult to ascribe any emotion to this whole endeavor other than love. You would think it'd get old at this point, but it hasn't. Every single article still feels like I am twelve years old, staring up at a great